FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4362542722> ?p ?o ?g. }

• W4362542722 endingPage "4020" @default.
• W4362542722 startingPage "4020" @default.
• W4362542722 abstract "Abstract Introduction: Bruton’s tyrosine kinase (BTK), a member of the Tec family, plays a crucial role in signaling through B-cell receptor (BCR). BTK inhibition blocks BCR signals and prevents B-cell activation and growth. First-generation BTK inhibitors such as ibrutinib covalently binds to a cysteine residue (C481) of BTK. Their most frequent acquired resistance is the development of a serine mutation in the binding site (C481S). Next generation BTK inhibitors such as LOXO-305 and ARQ 531 are being developed to overcome this resistance to first-generation inhibitors. Methods: HMPL-760 was tested in biochemical assays using recombinant human wild type (WT) and C481S mutant BTKs. Its selectivity was carried out using Eurofins Cerep KinaseProfilerTM panel. Cellular activity of HMPL-760 was evaluated in HEK293 cells stably transfected with BTKWT or BTKC481S, and other tumor cell lines, which are either human diffuse large B cell lymphoma (DLBCL) or mantle cell lymphoma (MCL) cell lines. The in vivo antitumor activity and PKPD correlation of HMPL-760 was studied in HBL-1 xenograft mouse models bearing BTKWT or BTKC481S respectively. Results: In biochemical assays, HMPL-760 strongly inhibits BTK kinase activities towards wild-type BTK (BTKWT) and C481S mutant (BTKC481S), and binds to BTK in a reversible way. HMPL-760 demonstrates high selectivity in a panel containing 413 kinases. In cellular assays, HMPL-760 displays strong anti-proliferative activities in B-cell lymphoma cells (TMD-8, OCI-LY10, REC-1, HBL-1 and HBL-1-BTKC481S) harboring either BTKWT or BTKC481S (GI50: 0.0015-0.046 μM). In human whole blood assay, HMPL-760 inhibits activation of B-cells at nanomolar concentrations measured by inhibition of immunoglobulin-induced CD69 expression in CD19+cells. HMPL-760 shows ≥ 10-fold inhibitory potency than ARQ 531 in both BTKWT and BTKC481S cells, and ~3-fold higher inhibitory potency than that of LOXO-305 in BTKC481S cells. In cellular assay by detecting p-BTK after compound washout, HMPL-760 maintains a longer duration of target inhibition than LOXO-305 in both BTK wild type (HBL-1) and BTK mutant (HBL-1-BTKC481S) cell lines. HMPL-760 displays dose-dependent antitumor efficacy in multiple human B cell lymphoma xenograft models in mice when orally administered at 3~50 mg/kg once daily. Complete tumor regression occurs in most of the tested models at the high dose levels. HMPL-760 shows much stronger antitumor efficacy than LOXO-305 and ARQ 531 at similar dose level, which may be associated with HMPL-760’s higher drug exposures and more sustainable inhibition on BTK phosphorylation in the tumor tissues. Conclusion: HMPL-760 is a reversible, selective, highly potent, BTK inhibitor targeting both BTKWT and BTKC481S. The first-in-human Phase 1 clinical trials of HMPL-760 are under way in patients with r/r B-NHL (NCT05190068, NCT05176691). Citation Format: Linfang Wang, Junqing Liang, Zhihu Gao, Jia Hu, Weigang He, Xianwen Yang, Fangfang Mao, Wei Zhang, Ying Yu, Qihang Zhang, Na Yang, Chun Zhang, Jian Wang, Yu Cai, Xiong Li, Weiguo Qing, Guangxiu Dai, Yongxin Ren, Michael Shi, Weiguo Su. HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4020." @default.
• W4362542722 created "2023-04-06" @default.
• W4362542722 creator A5010454129 @default.
• W4362542722 creator A5011875487 @default.
• W4362542722 creator A5014113912 @default.
• W4362542722 creator A5023697164 @default.
• W4362542722 creator A5027534949 @default.
• W4362542722 creator A5032764121 @default.
• W4362542722 creator A5037378054 @default.
• W4362542722 creator A5044777415 @default.
• W4362542722 creator A5059732688 @default.
• W4362542722 creator A5061624614 @default.
• W4362542722 creator A5063286511 @default.
• W4362542722 creator A5065042763 @default.
• W4362542722 creator A5067297050 @default.
• W4362542722 creator A5075996595 @default.
• W4362542722 creator A5076699095 @default.
• W4362542722 creator A5082399148 @default.
• W4362542722 creator A5082586117 @default.
• W4362542722 creator A5083868441 @default.
• W4362542722 creator A5086038672 @default.
• W4362542722 creator A5086934115 @default.
• W4362542722 date "2023-04-04" @default.
• W4362542722 modified "2023-09-28" @default.
• W4362542722 title "Abstract 4020: HMPL-760 is a highly potent and selective reversible BTK inhibitor, targeting BTK and BTKC481S in B-cell malignancies" @default.
• W4362542722 doi "https://doi.org/10.1158/1538-7445.am2023-4020" @default.
• W4362542722 hasPublicationYear "2023" @default.
• W4362542722 type Work @default.
• W4362542722 citedByCount "0" @default.
• W4362542722 crossrefType "journal-article" @default.
• W4362542722 hasAuthorship W4362542722A5010454129 @default.
• W4362542722 hasAuthorship W4362542722A5011875487 @default.
• W4362542722 hasAuthorship W4362542722A5014113912 @default.
• W4362542722 hasAuthorship W4362542722A5023697164 @default.
• W4362542722 hasAuthorship W4362542722A5027534949 @default.
• W4362542722 hasAuthorship W4362542722A5032764121 @default.
• W4362542722 hasAuthorship W4362542722A5037378054 @default.
• W4362542722 hasAuthorship W4362542722A5044777415 @default.
• W4362542722 hasAuthorship W4362542722A5059732688 @default.
• W4362542722 hasAuthorship W4362542722A5061624614 @default.
• W4362542722 hasAuthorship W4362542722A5063286511 @default.
• W4362542722 hasAuthorship W4362542722A5065042763 @default.
• W4362542722 hasAuthorship W4362542722A5067297050 @default.
• W4362542722 hasAuthorship W4362542722A5075996595 @default.
• W4362542722 hasAuthorship W4362542722A5076699095 @default.
• W4362542722 hasAuthorship W4362542722A5082399148 @default.
• W4362542722 hasAuthorship W4362542722A5082586117 @default.
• W4362542722 hasAuthorship W4362542722A5083868441 @default.
• W4362542722 hasAuthorship W4362542722A5086038672 @default.
• W4362542722 hasAuthorship W4362542722A5086934115 @default.
• W4362542722 hasConcept C153911025 @default.
• W4362542722 hasConcept C170493617 @default.
• W4362542722 hasConcept C185592680 @default.
• W4362542722 hasConcept C203014093 @default.
• W4362542722 hasConcept C2777938653 @default.
• W4362542722 hasConcept C2778461978 @default.
• W4362542722 hasConcept C2779878957 @default.
• W4362542722 hasConcept C42362537 @default.
• W4362542722 hasConcept C43907098 @default.
• W4362542722 hasConcept C502942594 @default.
• W4362542722 hasConcept C54355233 @default.
• W4362542722 hasConcept C55493867 @default.
• W4362542722 hasConcept C62478195 @default.
• W4362542722 hasConcept C81885089 @default.
• W4362542722 hasConcept C86803240 @default.
• W4362542722 hasConcept C90059517 @default.
• W4362542722 hasConceptScore W4362542722C153911025 @default.
• W4362542722 hasConceptScore W4362542722C170493617 @default.
• W4362542722 hasConceptScore W4362542722C185592680 @default.
• W4362542722 hasConceptScore W4362542722C203014093 @default.
• W4362542722 hasConceptScore W4362542722C2777938653 @default.
• W4362542722 hasConceptScore W4362542722C2778461978 @default.
• W4362542722 hasConceptScore W4362542722C2779878957 @default.
• W4362542722 hasConceptScore W4362542722C42362537 @default.
• W4362542722 hasConceptScore W4362542722C43907098 @default.
• W4362542722 hasConceptScore W4362542722C502942594 @default.
• W4362542722 hasConceptScore W4362542722C54355233 @default.
• W4362542722 hasConceptScore W4362542722C55493867 @default.
• W4362542722 hasConceptScore W4362542722C62478195 @default.
• W4362542722 hasConceptScore W4362542722C81885089 @default.
• W4362542722 hasConceptScore W4362542722C86803240 @default.
• W4362542722 hasConceptScore W4362542722C90059517 @default.
• W4362542722 hasIssue "7_Supplement" @default.
• W4362542722 hasLocation W43625427221 @default.
• W4362542722 hasOpenAccess W4362542722 @default.
• W4362542722 hasPrimaryLocation W43625427221 @default.
• W4362542722 hasRelatedWork W1780111622 @default.
• W4362542722 hasRelatedWork W2154945466 @default.
• W4362542722 hasRelatedWork W2172629347 @default.
• W4362542722 hasRelatedWork W2554863425 @default.
• W4362542722 hasRelatedWork W2557815702 @default.
• W4362542722 hasRelatedWork W2767548364 @default.
• W4362542722 hasRelatedWork W3003862081 @default.
• W4362542722 hasRelatedWork W3010122964 @default.
• W4362542722 hasRelatedWork W3184389017 @default.
• W4362542722 hasRelatedWork W3210817501 @default.
• W4362542722 hasVolume "83" @default.
• W4362542722 isParatext "false" @default.

• next